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Abstract Significant progress has been made in the
molecular diagnostic subtyping of brain tumors, in particular
gliomas. In contrast to the classical molecular markers in
this field, p53 and epidermal growth factor receptor (EGFR)
status, the clinical significance of which has remained con-
troversial, at least three important molecular markers with
clinical implications have now been identified: 1p/19q
codeletion, O6-methylguanine methyltransferase (MGMT)
promoter methylation and isocitrate dehydrogenase-1
(IDH1) mutations. All three are favorable prognostic
markers. 1p/19q codeletion and IDH1 mutations are also
useful to support and extend the histological classification of
gliomas since they are strongly linked to oligodendroglial
morphology and grade II/III gliomas, as opposed to glio-
blastoma, respectively. MGMT promoter methylation is the
only potentially predictive marker, at least for alkylating
agent chemotherapy in glioblastoma. Beyond these classical
markers, the increasing repertoire of anti-angiogenic agents
that are currently explored within registration trials for
gliomas urgently calls for efforts to identify molecular
markers that predict the benefit derived from these novel
treatments, too.
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Introduction: principles of modern patient care
in neuro-oncology
Clinical neuro-oncology has considerably changed and
developed within the last decade. Out of the most
important diagnostic disciplines, pathology and radiology,
two novel strong subspecialties, neuropathology and
neuroradiology, have emerged. At modern clinical neuro-
oncology centers, management and treatment has become
multidisciplinary, including neurosurgery, neurology
including epileptology, radiation oncology, medical and
pediatric oncology, as well as psychological oncology and
palliative care. These disciplines are ideally cooperating
under the umbrella of a Neuro-Oncology Center with
standardized diagnostic and therapeutic procedures
(Fig. 1). Such structures are necessary to face the
increasing challenges in neuro-oncology which derive
from the vast heterogeneity of intrinsic brain tumors, the
increasing rates of involvement of the nervous system by
systemic cancer, and the major risk of nervous system
complications as significant side effects of current cancer
therapies.
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Standards of care in glioma treatment
The current standard of care and treatment options for the
most common types of glioma are summarized in Table 1.
Some of the treatment recommendations remain contro-
versial, in particular for the management of grade II
gliomas. While many authors advocate maximal surgical
resection with both therapeutic and diagnostic objective for
patients with radiologically well delineated and circum-
scribed low-grade gliomas, others propose only close
follow-up and deferred surgery. However, since the diag-
nostic specificity of contemporary MRI techniques to
separate anaplastic gliomas from suspected low-grade gli-
omas is limited [23], at least a diagnostic biopsy should be
performed even in diffuse, non-delineated tumors. Once
diagnosis is established and surgery is not considered, both
radiotherapy and chemotherapy are effective treatments
[24], with more data available for radiotherapy, but both
treatment approaches may carry significant risks of side
effects, and there is no indication that early treatment
prolongs overall survival or even impacts survival in good
quality of life and in a neurologically less impaired con-
dition. For high-risk patients or patients with progressive
and symptomatic disease, radiotherapy has historically
been the standard treatment, whereas chemotherapy and
especially chemoradiotherapy are still investigational.
Long-term toxicity is a particular concern with any treat-
ment in a patient population with a life expectancy of
several to many years. Age [ 40 years, tumor size [
5–6 cm, tumors crossing the midline, neurologic deficits
and contrast enhancement on imaging are considered
unfavorable prognostic factors. The presence of 3 or more
of these risk factors has been shown to be associated with a
significantly shorter survival [17]. More aggressive treat-
ment is commonly recommended for patients with less
favorable prognostic factors, but it has remained uncertain
whether this patient population derives more benefit from
these treatments than patients with favorable prognostic
factors [24].
Standard treatment of newly diagnosed anaplastic gli-
oma (WHO grade III) includes resection where feasible,
followed by focal radiotherapy up to 60 Gy. Two large
international randomized trials have evaluated the benefit
of the addition of chemotherapy using procarbazine,
CCNU and vincristine (PCV) to radiotherapy, either before
or after radiotherapy. No difference in overall survival was
shown despite a trend toward improved progression-free
survival [4, 28]. Even in the subgroup of presumed che-
mosensitive oligodendrogliomas, no advantage for the
early use of chemotherapy was demonstrated. Recently, the
German Neuro-Onkologische Arbeitsgemeinschaft (NOA)-
04 trial showed that chemotherapy may substitute for
radiotherapy as initial postoperative therapy, with adequate
crossover and again no difference in overall survival was
shown with either of the sequence strategies [35]. For
patients presenting recurrent or progressive disease after
prior radiotherapy, temozolomide chemotherapy has dem-
onstrated high response rates in anaplastic astrocytoma and
mixed oligoastrocytoma [39] (Table 1).
There is not much controversy in the management of
newly diagnosed glioblastoma since a large randomized
phase III trial conducted by the EORTC and NCIC
demonstrated superiority of concomitant and adjuvant
(maintenance) temozolomide chemotherapy in addition to
radiotherapy compared to radiotherapy alone. Patients
with a WHO performance status of 0–2 and an age up to
70 years were included in this trial [25, 26]. The value of
radiotherapy was recently confirmed in a small random-
ized trial comparing best supportive care (only steroids
and supportive medicine) versus radiotherapy alone:
median survival was 29 weeks with radiotherapy com-
pared with 16.9 weeks with supportive care only [11].
Based on the overall shorter survival in elderly patients,
exclusive radiotherapy, often hypofractionated radiother-
apy is proposed to patients over age 65–70 years [20].
Two randomized trials presented in abstract form at the
Annual Meeting of the American Society of Clinical
Oncology in June 2010 failed to show superiority of
primary temozolomide chemotherapy in elderly patients
Fig. 1 Interdisciplinary patient care in neuro-oncology
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[15, 36]. In fact, the German NOA-08 trial even shows
that primary temozolomide alone is not non-inferior to
primary radiotherapy alone [36]. A concomitant treatment
strategy is currently evaluated in a NCIC-EORTC ran-
domized trial.
There is no accepted standard treatment for patients
recurring after prior chemoradiotherapy. Treatment options
depend on the delay after prior therapy, the patient‘s gen-
eral and neurological condition, and the requirement for
high-doses of corticosteroids. Cytotoxic options to be
considered are reexposure to temozolomide, possibly with
a metronomic or dose-intense regimen, at least in patients
failing during adjuvant rather than after adjuvant tem-
ozolomide or nitrosoureas [34]. A number of targeted or
antiangiogenic agents have failed to demonstrate measur-
able efficacy in randomized trials, e.g., erlotinib, imatinib,
or most recently, enzastaurin. The monoclonal antibody to
vascular endothelial growth factor (VEGF), bevacizumab,
has received substantial attention over the last 2 years.
Based on impressive radiological response rates, decreased
steroid requirements, but in the absence of a randomized
trial or the demonstration of a survival advantage, bev-
acizumab has received accelerated conditional FDA
approval in 2009, however, the European Medicines
Agency (EMEA) denied extension of the market applica-
tion [7, 12]. Despite occasional undeniable benefit, many
questions and concerns regarding utility, indication, dose
and schedule and efficacy remain for bevacizumab use in
malignant glioma [38].
Significance of molecular diagnostics in clinical trials
Molecular diagnostics allows identifying subgroups and
subtypes of glioma with a similar genetic profile. This
enrichment of more homogeneous patient populations may
lead to more uniform tumor responses in specific molecular
constellations. In particular, for therapy with modern tar-
geted agents, such a selective approach is warranted, as it
will exclude patients least likely to benefit from an inves-
tigational treatment strategy. Furthermore, as many of
these molecular markers carry a strong prognostic value,
stratification for known clinical and molecular prognostic
markers is important to adequately evaluate the outcome
and value of the new agent. In contrast to prognostic
markers that will estimate the outcome in a treatment-
independent manner, e.g., older glioma patients do worse
than younger glioma patients, predictive markers are of
value only in the context of a specific therapy, e.g., hor-
mone receptors in breast cancer or MGMT promoter
methylation in glioblastoma. However, in reality, markers
are often to some extent both of prognostic and of pre-
dictive value. Examples of molecular marker used for
selection or stratification within clinical trials are given in
Figs. 2, 3 and 4.
Thus, patient enrolment may be limited to patients
having gliomas with a particular molecular phenotype,
e.g., MGMT promoter methylation in the CENTRIC trial
for newly diagnosed glioblastoma. Further, molecular
markers can be determined upfront and used for patient
Table 1 Standards of care for malignant gliomas
Newly diagnosed Recurrence or progressiona
Diffuse astrocytoma WHO
grade II
Resection/biopsy and observation
or
resection/biopsy and radiotherapy
(Re-resection and) radiotherapy or chemotherapy
Oligodendroglioma and
oligoastrocytoma WHO
grade II
Resection/biopsy and observation
or
resection/biopsy and chemotherapy or radiotherapy
(Re-resection and) chemotherapy or radiotherapy
Anaplastic astrocytoma WHO
grade III
Resection/biopsy and radiotherapy or chemotherapyb (Re-resection and) chemotherapy (temozolomide
or nitrosourea) or re-irradiation
Anaplastic oligodendroglioma
and anaplastic
oligoastrocytoma
WHO grade III
Resection/biopsy and chemotherapy (PCV or
temozolomide)b or radiotherapyb or combined modality
treatmentc
(Re-resection and) radiotherapy or chemotherapy
(temozolomide or nitrosourea)
Glioblastoma
WHO grade IV
Resection/biopsy and radiotherapy and chemotherapy
(temozolomide)d
(Re-resection and) chemotherapy (temozolomide,
nitrosourea) or re-irradiation or bevacizumabe
a Please note that treatment at recurrence or progression depends on prior therapy
b See NOA-04 trial [35]
c See EORTC 26951 and RTOG 94-02 [4, 28]
d See EORTC 26981-22981 NCIC CE.3 [25, 26]
e See [12] and Table 3
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stratification, in order to prevent imbalances of favorable
versus non-favorable prognostic subgroups between treat-
ment arms. Ultimately, molecular diagnostics may be used
to determine whether specific biomarkers predict outcome
in response to a specific type of treatment. In this regard, a
prognostic marker is commonly considered a marker that
allows estimating the outcome in a treatment-independent
manner, whereas a predictive marker allows estimates of
outcome depending on treatment. For instance, the 1p/19q
codeletion (see below) is strongly predictive of a favorable
outcome in patients with grade III gliomas treated with
radiotherapy or chemotherapy [4, 28, 29, 35]. In contrast,
analyses of patients with grade II gliomas managed by
surgery alone showed the 1p/19q deletion to be associated
with slower growth in a French series [19], but not with
time to progression in a German study [31].
The EORTC trial 22033-26033 is a randomized phase
III study that evaluates primary chemotherapy with tem-
ozolomide versus radiotherapy in patients with grade II
astrocytic brain tumors. Patients are stratified for 1p loss to
make sure that prognostically similar patient populations
are randomized into both arms. MGMT promoter methyl-
ation will be assessed to determine whether the MGMT
status allows to predict specifically the benefit derived from
temozolomide chemotherapy.
For anaplastic oligodendroglial tumors, the 1p/19q
codeletion has traditionally been an important molecular
marker linked to a better prognosis, whereas other markers
have not gained major clinical significance (Table 2). The
RTOG 94-02 and EORTC 26951 prospective randomized
trials which compared radiotherapy alone with radiother-
apy followed by PCV, or PCV followed by radiotherapy,
demonstrated that the 1p/19q codeletion was associated
with longer progression-free survival and overall survival
and that this effect was independent of the initial treatment,
radiotherapy alone or radiotherapy with (neo-)adjuvant
chemotherapy [4, 28]. Thus, the 1p/19q status could no
Fig. 2 Clinical trial designs based on molecular diagnostics: CAT-
NON (http://www.ClinicalTrials.gov Identifier NCT00626990)
Fig. 3 Clinical trial design based on molecular diagnostics: CODEL
(http://www.ClinicalTrials.gov Identifier NCT00887146)
Fig. 4 Clinical trial design
based on molecular
diagnostics: CENTRIC
(http://www.ClinicalTrials.gov
Identifier NCT00689221)
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longer be claimed to specifically predict chemosensitivity
and therefore also not be used to guide treatment decisions
in terms of radiotherapy versus chemotherapy. In contrast,
it is solely a prognostic marker at present. This conclusion
was supported by the NOA-04 trial which enrolled 318
patients with all three types of anaplastic glioma and ran-
domized between radiotherapy alone and chemotherapy
alone, using either the PCV regimen or temozolomide [35].
Again, the 1p/19q codeletion was linked with a favorable
outcome irrespective of initial therapy. Based on EORTC
26951 and RTOG 94-02 [4, 28], EORTC, NCIC, RTOG,
MRC and HUB designed separate trials for 1p/19q-intact
and 1p/19q-codeleted tumors irrespective of the morpho-
logical subtype of anaplastic glioma (Figs. 2, 3). The four-
armed trial CATNON for patients without 1p/19q loss
examines the role of temozolomide in the concurrent or
adjuvant setting with radiotherapy, or both. Patients are
stratified for MGMT gene promoter methylation status.
CODEL, the companion protocol for 1p/19q-codeleted
tumors, will compare radiotherapy alone, temozolomide
chemotherapy alone and radiochemotherapy using tem-
ozolomide, thus combining features of NOA-04 [35] and
EORTC 26981-22981 NCIC CE.3 [25, 26].
The EORTC NCIC trial for temozolomide in newly
diagnosed glioblastoma had shown an increase of the
median survival from 12.1 to 14.6 months and of the 2-
year survival rate from 10 to 26% when temozolomide was
added to radiotherapy. The benefit from temozolomide was
particularly prominent in patients with tumors exhibiting
MGMT promoter methylation [8]. The difference in pro-
gression-free survival among the MGMT-methylated
patients of 5.9 months with radiotherapy alone versus
10.3 months with radiotherapy plus temozolomide sug-
gested that indeed MGMT promoter methylation is a
predictive molecular marker for benefit from temozolo-
mide. No confirmation of this finding from another trial
may be expected, since radiotherapy alone is no longer an
accepted standard of care control arm in trials except for
older patients with glioblastoma. Many ensuing phase II
trials that examined radiotherapy plus temozolomide plus
another (novel) agent confirmed that MGMT promoter
methylation was at least prognostic in newly diagnosed
glioblastoma. Compared with the historical data base of the
EORTC NCIC trial [8, 25], a gain in median progression-
free survival specifically in patients with glioblastoma with
MGMT promoter methylation was observed in a trial
examining the first-in-class integrin-targeting polypeptide,
cilengitide [27]. Accordingly, the CENTRIC trial, a
cooperative effort of EORTC and Merck Serono, seeks
approval for cilengitide specifically in the subset of patients
(30–35%), whose glioblastomas exhibit MGMT promoter
methylation.
Thus, altogether, molecular diagnostics of gliomas may
serve the purposes to allow for the definition of more
homogeneous patient populations as exemplified in CAT-
NON and CODEL for anaplastic gliomas or CENTRIC for
glioblastoma (Figs. 2, 3, 4) or may, in the future, be used to
test whether specific treatments are active depending on the
absence or presence of a specific molecular marker. While
1p/19q status and MGMT status are thus already used for
patient enrolment, the determination of IDH1 mutations
may assume an important diagnostic role in the near future.
Glioblastomas with IDH1 mutations have a much better
prognosis and putatively a different histogenetic origin,
further supported by the recent discovery of a glioma-CpG
island methylator phenotype (G-CIMP) associated with
IDH1 mutations [16]. CIMP has been identified also in
other cancers, best known from colon cancer, and usually
defines a distinct subtype with different epidemiology and
distinct clinical and molecular features [9]. Hence, future
glioblastoma trials should either exclude these patients or
introduce a stratification for the IDH1 mutation status.
Significance of molecular diagnostics in the routine
diagnostic assessment
Considerable efforts have been made for two decades to
implement molecular diagnostics in the subclassification of
glioblastoma, often with the view to aid clinicians in
decision making. Such studies have traditionally focused
on molecular lesions that are thought to be involved in the
molecular pathogenesis of glioblastoma, e.g., mutations of
p53 or phosphatase-and-tensin-homolog-on-chromosome-
ten (PTEN) or amplification of the epidermal growth factor
receptor (EGFR) or cyclin-dependent kinase (CDK) 4
Table 2 Molecular markers in
glioma: prognostic or
predictive?
Grade II gliomas Grade III anaplastic gliomas Grade IV glioblastoma
P53 mutations No No No
EGFR amplification No No No
1p/19q codeletion Controversial Prognostic (pos.) Rare
MGMT promoter methylation Controversial Prognostic (pos.) Predictive for alkylating
agent chemotherapy
IDH 1/2 mutations Prognostic (pos.) Prognostic (pos.) Rare, prognostic (pos.)
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genes. Interestingly, however, once the glioblastoma phe-
notype has been established, the absence or presence of
these lesions does not correlate with the outcome of
patients treated according to current standards of care [32].
In fact, none of the molecular markers available today,
including those compiled in Table 2, are particularly
helpful in daily decision making. Furthermore, targeting
the EGFR signaling pathway using small molecule inhib-
itors has not shown the benefit hoped for [2]. Available
data from clinical trials does not support particular treat-
ments or treatment strategies based on the molecular
profile. This is particularly true for grade II gliomas, where
the prognostic role of all molecular markers with the
exception of IDH1 mutations has remained more contro-
versial. Probably there is a prognostic role of 1p/19q and
MGMT promoter methylation in low-grade gliomas, too,
but the magnitude of effect may be smaller than in ana-
plastic gliomas [10]. Accordingly, molecular markers
cannot be used to decide whether a patient should receive
genotoxic therapy or not, and if so, radiotherapy or che-
motherapy. While IDH1 mutations are prognostically
favorable across all grades of gliomas (Table 2) [21], no
study has demonstrated a link between this molecular
lesion and benefit from a specific type of treatment [6].
Among anaplastic gliomas, anaplastic oligodendroglial
tumors were traditionally believed to have a better prognosis
than anaplastic astrocytomas, while mixed oligoastrocyto-
mas were attributed an intermediate prognosis, and
chemosensitivity was believed to be linked to the 1p/19q
codeletion [4]. It has become clear that the 1p/19q codele-
tion is predictive for a more favorable course in response to
either chemotherapy with PCV or temozolomide or radio-
therapy, and, in fact, in anaplastic gliomas, this is true for
MGMT promoter methylation as well as IDH1 mutations
[29, 30, 35]. These three favorable markers are not inde-
pendent, but partly associated, e.g., the 1p/19q codeletion
lost significance upon the multivariate analysis of the
NOA-04 trial when MGMT and IDH1 status were included
in the analysis, whereas IDH1 mutation and MGMT pro-
moter methylation were strongly correlated in other studies
[30]. In conclusion, all three markers are helpful in daily
clinical routine because they provide powerful information
for patient counseling in terms of overall prognosis, yet,
there is no rationale to base treatment decisions on either of
these markers.
1p/19q codeletions and IDH1 mutations are rare in glio-
blastomas and may even be considered incompatible with
the diagnosis of glioblastoma in the future. In contrast,
MGMT promoter methylation is often advocated as a valu-
able biomarker allowing to guide treatment decisions in
glioblastoma patients even outside clinical trials. This
common practice should be discouraged for many reasons,
as recently reviewed elsewhere [33]: only the methylation-
specific PCR has repeatedly provided clinically useful
prognostic information, whereas all other techniques of
assessing the MGMT status must be considered experimental
and require further study; even the methylation-specific
PCR did not yield reproducible data across laboratories; and
withholding temozolomide on the basis of an unmethylated
MGMT promoter test means withholding the only proven
active drug against glioblastoma from a majority of patients.
Clinical perspectives for molecular diagnostics
The promising development of anti-angiogenic agents in
glioblastoma (Table 3) calls for the search for novel
prognostic or predictive markers which might guide the
choice for or against agents with specific modes of actions
in the future. For instance, one might predict that only
glioblastomas expressing high levels of VEGF will respond
to bevacizumab or cediranib, whereas sensitivity to cilen-
gitide would require expression of the corresponding target
integrins, avb3 and avb5, on blood vessels or tumor cells or
Table 3 Vasculature-targeting agents explored in registration trials for glioblastoma
Mode of action Newly diagnosed Recurrent
Bevacizumab VEGF antibody Phase II combination with RT/TMZ ? TMZ safe [14]
Phase III recruiting (AVAGLIO)
Phase II promising [7, 12]
Cediranib VEGF receptor
antagonist
Phase II combination with RT/TMZ ? TMZ planned
(RTOG)
Phase II monotherapy promising [1]
Phase III combination with lomustine
(REGALa)
Cilengitide Integrin antagonist Phase II combination with RT/TMZ ? TMZ promising
[27]
Phase III recruiting (CENTRIC)
Phase II monotherapy promising [18]
Enzastaurin PKCb-antagonist Phase I combination with RT/TMZ ? TMZ concluded
[3]
Phase I/II promising for response, but not PFS
[13]
Phase III monotherapy negative [37]
a http://www.ClinicalTrials.gov IDENTIFIER NCT00777153
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both. Visualization of the target molecule in vivo by
molecular imaging might be a technology in the future to
detect and monitor molecular markers for targeted thera-
pies [22]. Although intuitive, such studies have not yet
been performed or at least did not yield conclusive results.
This resembles the so far unsuccessful efforts at identifying
prospectively the minority of glioma patients which derive
benefit from EGFR inhibitors. These unexpected failures
are likely due to the underestimation of the complexity of
the targeted cancer-relevant pathways. Efforts are ongoing
to devise respective combination strategies [2].
Despite these drawbacks, there has been significant
progress in supporting and supplementing the histological
classification of gliomas with an increasing spectrum of
molecular markers with strong prognostic impact, and it
appears not too optimistic to assume that it may not take
long until the first markers with predictive power for spe-
cific treatments become available, as also seen in some few
other cancers.
Even today, the increasing use of molecular testing if
only for prognostic assessment has resulted in problems
and challenges that urgently need to be addressed: how are
such tests standardized, should there be reference labora-
tories, should most neuropathology units offer these tests,
and, finally, how can such a broadening of the neuro-
pathological diagnostic repertoire be financed to make it
available to most oncology centers in many countries? It is
unlikely that neuro-oncologists will always be so lucky
as to take an unexpected finding from high-throughput
analyses, such as the IDH1 mutations back to routine with a
simple PCR or more recently even a mutation-specific
antibody that can easily be incorporated into standard
immunohistochemistry procedures [5].
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